TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: nighttime glycaemic control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treadmill walking time to the development of moderate angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase of DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of recurring bladder cancer
Endpoint domain: Mortality/survival
Primary endpoint: risk of dying of bladder cancer
Endpoint domain: Mortality/survival
Primary endpoint: expensive hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Self-reported disability improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak systemic insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose Rd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suppression of HGP and plasma free fatty acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of total p-AF after LF-HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of free p-AF after LF-HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of protein-bound p-AF after LF-HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average variability in insulin sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Abnormal test results in patients with diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test scores comparison between patients with diabetes and normal controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test times comparison between patients with diabetes and normal controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority in safety and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical excitability measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urinary N‐nitrososarcosine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: weight z score at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height z score at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of CM symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrals of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in S. mutans levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of residual motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: duration of analgesic block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: surgical site bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: role overload
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Successfully quit smoking at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Waistline reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: increased total sleep time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: improved ratings of daytime ability to function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: leg extensor power improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Users' acceptability of the app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normal blood pressure achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in pain and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in RBPCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean RRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: volumetric wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain and/or sensory complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume reduction rate of individual tumor nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correction of pelvic obliquity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events during patient admissions
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of AUB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to the first heavy-drinking day posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin resistance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: N100 amplitude and latency to non-targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P300 latency to targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Receiving advice on avoiding sexually transmitted infections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Being given condoms
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subsequent condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of retinopathy of prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: visual acuity testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: gain in root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in PRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-sensitivity-C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: urinary albumin/creatinine ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mRS 0-1 at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BI >= 95 at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GOS of 0-1 at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phoneme recognition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Background noise subscale problem score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive benefits measured by Alzheimer's Disease Cooperative Study‐Activities of Daily Living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean stool volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in glycosylated hemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ex vivo mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of polyhydramnios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: perceived risk for STIs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients seen within 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to guideline recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Complicated Grief (CG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLN identification rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False negative rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body BMD loss prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Children determined to smoke in the future
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's first smoking attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alphaGST concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: endometrioma recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: moderate-to-severe pain recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to recurrence of symptoms or endometriomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: THA conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster gametocyte clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced gametocyte densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day 42 cure rate of asexual stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating EPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular end-diastolic volume index (EDVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in allopurinol users
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in benzbromarone users
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Induction of apoptosis in rectal cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative Blood Loss (PBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ANUBT (Analgesic Needed for Uncontrolled Breakthrough Pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area of hyperenhancement on CMR expressed as a percentage of the left ventricular myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of bowel and abdominal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in frequency of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in DAS28 at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of enamel decalcifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenofovir concentrations >40 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to PrEP (>80%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective effect of PrEP against HIV acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score (VRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rankin scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase of laser Doppler flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: decrease in the thickness of the echo-poor band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: inotrope duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat revascularization rates
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 24-hour IOP fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: peak IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: supplemental opioid medication usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores at rest and during activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in effective renal plasma flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of sensory blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of major birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Birth weights adjusted for gestational age and sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of oral supervised self-testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of oral supervised self-testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of acetaminophen and NSAID intake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Discriminating risk of nosocomial sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vo2 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean average thickness of RNFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentages prescribed β-blockers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean RULA score of the assistant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical discomfort for the assistant
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: NASA TLX score reduction
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: plasma IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: center point thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak levels of troponin I release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum myostatin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical fitness improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P50 response suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative expression rates of serum HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative expression rates of serum HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Involuntary detrusor activity resulting in incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress incontinence diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diameter stenosis at 6-months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise intensity prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: De novo DSA-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AHI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ODI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incident BPH/LUTS development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Creation of arthrodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VAPS scores on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication and interaction stimulation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Surface microhardness recovery ratio (%SMHRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raman intensity change ratio (%ICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color recovery ratio (%CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: executive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of severe anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for hypoglycemia treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases with pain relief in 10 min after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment intention scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severe sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total amount of bleeding during cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global knowledge about pre-eclampsia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety scores regarding pre-eclampsia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with educational tools
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glasgow Outcomes Scale-Extended for Pediatrics at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow Outcomes Scale-Extended for Pediatrics at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile hypersensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air blast hypersensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental quotients (DQs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CP and survival without neurosensory or cognitive impairment
Endpoint domain: Mortality/survival
Primary endpoint: maximum reach distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak vertical force during standing up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average blood loss at 2 hours postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrences of postpartum hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes